248 related articles for article (PubMed ID: 12805322)
21. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
22. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
van der Heijden AG; Moonen PM; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Barten EJ; Puri R; van Kalken CK; Witjes JA
J Urol; 2006 Oct; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
[TBL] [Abstract][Full Text] [Related]
23. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
24. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
25. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
Grampsas SA; Kahn K; Crawford ED
Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
[TBL] [Abstract][Full Text] [Related]
26. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
27. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311
[TBL] [Abstract][Full Text] [Related]
30. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
31. AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.
Malmström PU; Loskog AS; Lindqvist CA; Mangsbo SM; Fransson M; Wanders A; Gårdmark T; Tötterman TH
Clin Cancer Res; 2010 Jun; 16(12):3279-87. PubMed ID: 20448220
[TBL] [Abstract][Full Text] [Related]
32. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma.
Pan JJ; Zhang SW; Chen CB; Xiao SW; Sun Y; Liu CQ; Su X; Li DM; Xu G; Xu B; Lu YY
J Clin Oncol; 2009 Feb; 27(5):799-804. PubMed ID: 19103729
[TBL] [Abstract][Full Text] [Related]
33. P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder.
Shiraishi K; Eguchi S; Mohri J; Kamiryo Y
Anticancer Res; 2003; 23(4):3475-8. PubMed ID: 12926093
[TBL] [Abstract][Full Text] [Related]
34. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
[TBL] [Abstract][Full Text] [Related]
36. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo.
Bass C; Cabrera G; Elgavish A; Robert B; Siegal GP; Anderson SC; Maneval DC; Curiel DT
Cancer Gene Ther; 1995 Jun; 2(2):97-104. PubMed ID: 7621262
[TBL] [Abstract][Full Text] [Related]
37. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
[TBL] [Abstract][Full Text] [Related]
38. Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.
Azuma H; Kotake Y; Yamamoto K; Sakamoto T; Kiyama S; Ubai T; Inamoto T; Takahara K; Matsuki M; Segawa N; Shibahara N; Katsuoka Y
Am J Clin Oncol; 2008 Feb; 31(1):11-21. PubMed ID: 18376222
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]